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Background: New information from various clinical settings suggests that tight blood pressure control may not
reduce mortality and may be associated with more side effects.
Methods: We performed cross-sectional multivariable ordered logistic regression to examine the association
between predialysis blood pressure and the short physical performance battery (SPPB) in a cohort of 749 prevalent
hemodialysis patients in the San Francisco and Atlanta areas recruited from July 2009 to August 2011 to study the
relationship between systolic blood pressure and objective measures of physical function. Mean blood pressure for
three hemodialysis sessions was analyzed in the following categories: <110 mmHg, 110-129 mmHg (reference),
130-159 mmHg, and ≥160 mmHg. SPPB includes three components: timed repeated chair stands, timed 15-ft walk,
and balance tests. SPPB was categorized into ordinal groups (≤6, 7-9, 10-12) based on prior literature.
Results: Patients with blood pressure 130-159 mmHg had lower odds (OR 0.57, 95% CI 0.35-0.93) of scoring in a
lower SPPB category than those whose blood pressure was between 110 and 129 mmHg, while those with blood
pressure ≥160 mmHg had 0.56 times odds (95% CI 0.33-0.94) of scoring in a lower category when compared with
blood pressure 110-129 mmHg. When individual components were examined, blood pressure was significantly
associated with chair stand (130-159 mmHg: OR 0.59, 95% CI 0.38-0.92) and gait speed (≥160 mmHg: OR 0.59, 95%
CI 0.35-0.98). Blood pressure ≥160 mmHg was not associated with substantially higher SPPB score compared with
130-159 mmHg.
Conclusions: Patients with systolic blood pressure at or above 130 mmHg had better physical performance than
patients with lower blood pressure in the normotensive range. The risk-benefit tradeoff of aggressive blood pressure
control, particularly in low-functioning patients, should be reexamined.
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Recent studies have suggested the need for further exam-
ination of the relationship between blood pressure control
and physical function. The Action to Control Cardiovas-
cular Risk in Diabetes (ACCORD) trial showed more ad-
verse events among patients with diabetes randomly
assigned to a systolic blood pressure target of <120 mmHg
compared with a target of <140 mmHg without reduction
in cardiovascular outcomes [1]. Despite positive results of* Correspondence: kirsten.johansen@ucsf.edu
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sure control [2], several randomized studies have also
called into question the benefit of aggressive blood pres-
sure control among elderly or frail individuals [3]. A re-
cent study found that the association of high blood
pressure and mortality varied by walking speed in elderly
patients such that elevated blood pressure was not associ-
ated with higher mortality among patients with slow gait
speed [4]. Taken together, these findings raise the possibil-
ity that strict blood pressure control could contribute to
poor function among elderly or frail individuals by in-
creasing symptoms of dizziness and fatigue and lowering
physical activity and may increase the risk of adverse out-
comes without improving outcomes. Indeed, updatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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sure in adults have raised the recommended systolic blood
pressure treatment goal to <150 mmHg for individuals
aged 60 years or older, citing evidence of a lack of benefit
of treatment to lower targets [5].
Patients with poor physical function could be at higher
risk for these complications and simultaneously be less
likely to benefit. These issues are particularly relevant
among patients on hemodialysis because approximately
seventy-six percent of dialysis patients are prescribed anti-
hypertensive medications, and they experience significant
impairments in physical function that have been associ-
ated with higher mortality in chronic kidney disease and
community-dwelling elderly populations [6-9]. Although
studies have shown that rigorous exercise interventions
can improve physical function among patients with ESRD,
these interventions are resource-intensive and not access-
ible to all patients [10,11]. Thus, it is important to con-
sider other factors that might affect physical function in
this population.
We used data from the United States Renal Data System
(USRDS) ACTIVE/ADIPOSE (A Cohort study To Investi-
gate the Value of Exercise/Analyses Designed to Investi-
gate the Paradox of Obesity and Survival in ESRD) cohort,
which includes measurements that make up the short
physical performance battery (SPPB), to study the relation-
ship between levels of blood pressure and objective mea-
sures of physical function in hemodialysis patients. We
hypothesized that lower blood pressure would be associ-
ated with worse performance on the SPPB. In addition to
examining blood pressure that was frankly low, we were
also interested in examining whether blood pressure in
ranges considered to indicate good blood pressure control
would be associated with worse performance.Methods
The ACTIVE/ADIPOSE is a cohort study of the United
States Renal Data System (USRDS) Nutrition and Re-
habilitation/Quality of Life Special Studies Centers that
enrolled 778 prevalent hemodialysis patients from the San
Francisco Bay Area and the Atlanta metropolitan area be-
tween 2009 and 2011. The description of the ACTIVE/
ADIPOSE study and methods have been published else-
where [12]. English or Spanish-speaking patients who had
been on dialysis for at least 3 months were included. Study
participants provided written informed consent, and the
study was approved by the Institutional Review Boards at
Emory University and the University of California, San
Francisco. The study was conducted in adherence with the
Declaration of Helsinki.
We performed a cross-sectional analysis to examine the
association between predialysis systolic blood pressure
and components of the short physical performance batteryamong 749 patients who had blood pressure and physical
function data available.
Short physical performance battery (SPPB)
Our primary outcome, the SPPB was designed to assess
lower extremity function in community-dwelling elderly
individuals and includes three components: (1) timed re-
peated chair stands, (2) a timed 15-foot walk, and (3)
balance testing over ten seconds. We performed SPPB
assessments as described by Guralnik et al. prior to a
mid-week or end-of-week dialysis session [13].
Participants were asked to stand up from a chair and sit
down again five times repeatedly as quickly as possible. A
score of zero was given if a participant was unable to per-
form five chair stands. A score of one, two, three, or four
was assigned to a participant who completed five chair
stands in ≥16.7, 13.7-16.6, 11.2-13.6, and ≤11.1 seconds,
respectively.
Participants were asked to walk a marked 15-foot course
at a normal pace. Two trials were conducted, and the fas-
ter of the two walks was used for analysis. Gait speed was
calculated for each patient using distance in meters and
time in seconds. Patients were scored from 0 to 4, where 0
points indicated inability to perform the walk and 4 indi-
cated a gait speed of >0.83 m/s.
Balance testing was comprised of three components:
(1) semitandem stand (2) side-by-side stand and (3) tan-
dem stand. Participants began with a semi-tandem stand
where the heel of one foot was placed to the side of the
first toe of the other foot. Those who were able to stand
for 10 seconds in the semi-tandem stand position were
tested in the full tandem stand with the heel of one foot
directly in front of the toes of the other. Balance testing
was scored on a 0-4 scale with a score of 4 indicating a
full tandem stand for 10 seconds. Total SPPB score was
calculated by the sum of the components.
Blood pressure and antihypertensive medication
Although postdialysis blood pressure and 24-hour ambula-
tory blood pressure monitoring may be important predic-
tors of outcomes in the hemodialysis population [14,15],
we chose predialysis systolic blood pressure as our primary
predictor in this analysis because the SPPB was measured
prior to a dialysis session. Predialysis blood pressures taken
as part of routine care were recorded for the previous three
hemodialysis sessions before the study visit, and the mean
systolic blood pressure was used as the primary predictor.
We analyzed predialysis blood pressure in the following
categories: <110 mmHg, 110-129 mmHg, 130-159 mmHg,
and ≥160 mmHg. We chose these categories to be similar
to other studies examining outcomes related to blood pres-
sure among patients on hemodialysis. For example, pa-
tients with predialysis blood pressure less than 110 mmHg
had a higher risk of death in a US-based observational
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Dialysis Outcomes and Practice Patterns Study con-
cluded that survival was significantly better among
patients with predialysis SBP ≥130 mmHg and at facil-
ities with more patients at predialysis SBP 130 to <160
mmHg [17]. We separated patients with a blood pres-
sure of <110 mmHg from those with a blood pressure
of 110-129 mmHg to ensure that the results were not
driven by patients with very low blood pressure who
had poor physical function. Information about prescrip-
tion medication was carefully collected through chart
review, and the number of prescribed antihypertensive
medications was quantified for each participant.
Covariates
Data on comorbidities were obtained from the informa-
tion recorded on the Medical Evidence Form 2728 and
included in the USRDS. Comorbidities from the Medical
Evidence Form 2728 have been previously validated with
sensitivity being high for hypertension and diabetes and
intermediate for peripheral vascular disease, cerebrovas-
cular disease and heart failure [18]. Serum albumin was
measured by nephelometry. Covariates were selected
based on a clinical conceptual model and included age,
gender, African-American race, diabetes mellitus, heart
failure, coronary artery disease, stroke, peripheral vascular
disease, ESRD vintage (date of first ESRD hemodialysis
treatment), hemoglobin, body mass index, interdialytic
weight gain, and serum albumin concentrations. Interdia-
lytic weight gain was calculated by subtracting the postdia-
lysis weight from the predialysis weight of the subsequent
treatment and dividing by the postdialysis weight. The
most recent clinical hemoglobin level documented in the
chart was used for the analysis.
Statistical analysis
We compared patient characteristics using chi squared
tests, t-tests, Mann-Whitney U tests, and linear regression
as appropriate. Restricted cubic splines were generated to
examine the association between total SPPB score and
mean predialysis blood pressure.
We used univariate and multivariate ordinal logistic re-
gression with predialysis blood pressure categories as the
primary predictor and predialysis SBP of 110-129 mmHg
as the reference category. Models were constructed with
the SPPB and each of the component measures as out-
comes. Total SPPB score was categorized into three ordinal
groups (≤6, 7-9, 10-12) as performed in prior studies [19].
We examined all residuals of continuous variables for a
normal distribution and those with non-normal distribu-
tion (ESRD vintage) were log-transformed. Missing serum
albumin values (n = 15, 2%) were accounted for using mul-
tiple imputations. The multivariate model was run with
and without data on prescribed antihypertensives. Multiplebinary cutoffs were examined to ensure that the data met
the proportional odds assumption. Because medications
prescribed to treat heart failure or coronary heart disease
can lower blood pressure, we performed sensitivity analyses
excluding patients with each of these diagnoses. All ana-
lyses were completed using Stata 13 (StataCorp LP).
Results
The mean age of the cohort was 57.3 years (SD 14.2).
Patients in the highest blood pressure category were
more likely to be African American and have higher
interdialytic weight gains, while those in the lowest cat-
egory had lower serum albumin (3.8 ± 0.7 mg/dl) than
those in other groups (p = 0.02). Fifty-six percent of pa-
tients in the lowest blood pressure category and 75% of
patients in the 110-129 mmHg group were prescribed at
least one antihypertensive medication. There were no
statistically significant differences in prevalence of co-
morbidities based on blood pressure (Table 1).
A restricted cubic spline curve for the unadjusted as-
sociated between mean predialysis blood pressure and
SPPB score is displayed in Figure 1. Performance was
better at higher blood pressures, but the slope of this as-
sociation flattened above 151 mmHg. Examining SPPB
by category, 29% of participants scored ≤6 points and
45% scored ten or more points on the SPPB. The odds
ratio of scoring in a lower SPPB category (0-6) was 0.60
(95% CI 0.39-0.94) for participants with a predialysis
mean systolic blood pressure of ≥160 mmHg when com-
pared with the reference range of 110-129 mmHg in uni-
variate analysis. In a multivariate model, participants with
blood pressures 130-159 mmHg and ≥160 mmHg had sig-
nificantly lower odds of scoring in a lower SPPB category
(130-159 mmHg: OR 0.57 (95% CI 0.35-0.93), ≥160
mmHg: OR 0.56, (95% CI 0.33-0.94); Table 2). Blood pres-
sure less than 110 mmHg was not associated with worse
function than 110-129 mmHg (OR 0.82, 95% CI 0.32-2.09).
Diabetes mellitus, older age, peripheral artery disease,
stroke history, female gender, and African-American race
were associated with worse SPPB scores, and higher serum
albumin concentration was associated with higher scores.
Neither heart failure nor hemoglobin concentration was
significantly associated with physical performance.
The association between higher blood pressure and
higher SPPB score remained statistically significant when
the number of prescribed antihypertensive medications
was added to the model (130-159 mmHg: OR 0.58, 95%
CI 0.35-0.95), and there was no statistically significant
interaction between systolic blood pressure and number
of antihypertensive medications prescribed.
When we examined the individual components of the
SPPB in multivariable analysis, chair stand performance
and gait speed were significantly associated with blood
pressure while balance was not (Figure 2). The odds ratio
Table 1 Baseline characteristics of participants based on blood pressure category








N = 27 N = 92 N = 373 N = 257
Age (years) 56.2(15.1) 58.9(14.9) 58.2(14.4) 55.5(13.6) 0.07
Gender
▪Male 19(70%) 52(57%) 234(63%) 139 (54%) 0.09
Race
▪White 5(19%) 31(34%) 103 (28%) 39(15%) <0.001
▪African American 14(52%) 48 (52%) 207(56%) 192(75%)
▪Other* 8(30%) 13(14%) 63(17%) 26(10%)
Comorbidities
▪Coronary Artery Disease 5(19%) 10(11%) 30(8%) 21(8%) 0.26
▪Diabetes Mellitus 10(37%) 34(37%) 179(48%) 122(47%) 0.19
▪Stroke 1(4%) 5(5%) 15(4%) 12(5%) 0.93
▪Heart Failure 7(26%) 18(20%) 75(20%) 42(16%) 0.51
▪Peripheral Vascular Disease 4(15%) 12(13%) 34(9%) 22(9%) 0.47
Laboratory Values
▪Hemoglobin (g/dl) 11.4(1.3) 11.3(1.3) 11.8(3.1) 11.8(2.4) 0.38
▪Albumin (g/dl) 3.8 (0.7) 4.0(0.3) 4.0(0.3) 4.0(0.4) 0.02
ESRD Vintage (years) [median, (25th, 75th
percentile)]
4.3 (2.1,10.5) 3.2(1.5,6.0) 2.8(1.3,6.0) 3.7(1.7,7.4) 0.08
Number of antihypertensive prescribed [median,
(25th, 75th percentile)]
1(0,1) 1.5(0.5, 3) 2(1,3) 3 (2,3) <0.001
Body Mass Index (kg/m2)ơ
▪ < 20 0(0%) 8(9%) 13(4%) 10(4%) 0.004
▪20-24.99 3 (11%) 24(26%) 100(27%) 88(34%)
▪25-29.99 6(22%) 32(35%) 109(29%) 75(29%)
▪30-34.99 10(37%) 13(14%) 80(21%) 41(16%)
▪ ≥ 35 1(4%) 1(1%) 1(0.2%) 0(0%)
Average IDWG (%) 2.8(1.8) 3.2(1.8) 3.4(1.9) 3.5(1.9) 0.005
┼p-value refers to χ2 test (for gender, race, BMI, and comorbities), linear regression for continuous variables (age, hemoglobin, albumin, hemodialysis
vintage, antihypertensives).
*Includes 1 missing race value.
ơIncludes 1 missing value from each of the following categories: <110, 110-129, 130-159.
IDWG: Interdialytic weight gain, expressed as a percentage of predialysis body weight.
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0.38-0.92) in the 130-159 mmHg group and 0.66 (95% CI
0.41-1.05) for the ≥160 mmHg group when compared to
the reference group. The odds ratio of scoring in a lower
category of walking speed was 0.65 (95% CI 0.40-1.07) for
the 130-159 mmHg category and 0.59 (95% CI 0.35-0.98)
for the ≥160 mmHg group when compared with the refer-
ence group. Results of the multivariate models for chair
stand, gait speed, and balance are displayed in Figure 2.
Sensitivity analyses
Because antihypertensive medications used in the treat-
ment of heart failure or coronary artery disease could influ-
ence predialysis blood pressure, we conducted sensitivityanalyses excluding participants with these diagnoses. When
patients with heart failure (n = 142) were excluded from
the primary analysis, the odds of scoring in a lower SPPB
category remained similar (130-159 mmHg: OR 0.58, 95%
CI 0.33-1.00; ≥160 mmHg: OR 0.57, 95% CI 0.33-1.00).
When patients with coronary heart disease were excluded
from the analysis (n = 66), the point estimates were also
similar (130-159 mmHg: OR 0.61, 95% CI 0.36-1.03; ≥160
mmHg: OR 0.59, 95% CI 0.34-1.02).
Discussion
We have demonstrated that a predialysis systolic blood
pressure of 130 mmHg or more is associated with better
physical performance on the SPPB when compared with
Table 2 Odds ratio of scoring in a lower SPPB category
OR (95% CI) p-value






Age (per 10 yrs) 1.83(1.60-2.09) <0.001
Male 0.47(0.34-0.65) <0.001
African-American race 1.77(1.25-2.50) 0.001
Comorbidity
Stroke 2.29(0.98-5.35) 0.06
Diabetes mellitus 1.95(1.40-2.73) <0.001
Serum albumin (per 0.5 g/dl) 0.55(0.44-0.68) <0.001
Peripheral Vascular Disease 3.77(2.09-6.81) <0.001
Hemoglobin 0.95(0.89-1.02) 0.2
Heart Failure 1.44(0.96-2.16) 0.08
Coronary artery disease 1.10(0.62-1.98) 0.74
ESRD vintage (log) 1.06(0.92-1.23) 0.38







IDWG: Interdialytic weight gain as a percentage of predialysis body weight.
Figure 1 Spline curve for the unadjusted association between
mean predialysis systolic blood pressure and short physical
performance battery score (solid line) with 95% confidence
intervals (dashed lines).
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http://www.biomedcentral.com/1471-2369/15/177a predialysis systolic blood pressure of 110-129 mmHg
among patients on hemodialysis. The relationship between
low blood pressure and physical performance persisted
even after adjustment for age and important comorbidities
and even when we adjusted for number of prescribed anti-
hypertensive medications. When the components of the
SPPB were considered separately systolic blood pressure
110-129 mmHg was associated with worse chair stand
when compared with 130-159 mmHg. Although both of
the higher blood pressure categories were associated with
higher SPPB score, a systolic blood pressure of ≥160
mmHg was not associated with a substantial improvement
in SPPB score when compared to 130-159 mmHg. This
finding suggests that raising the systolic blood pressure
target as recently recommended by the JNC 8 for older in-
dividuals could optimize physical performance without the
adverse events that are associated with systolic blood pres-
sures greater than 160 mmHg among patients on dialysis
[5]. It was particularly notable in our study that 56% of pa-
tients with systolic blood pressure <110 mmHg and 75%
of those with systolic blood pressure 110-129 mmHg were
prescribed at least one blood pressure medication.
Prior studies in non-dialysis populations have shown
that strict blood pressure control may not improve sur-
vival beyond conventional control. The ACCORD trial
revealed that strict blood pressure control in patients
with diabetes was not associated with a statistically sig-
nificant improvement in survival and led to more ad-
verse events [1]. Among dialysis patients, observational
studies have described a J-shaped phenomenon in which
patients with predialysis blood pressures less than 120
mmHg had higher cardiovascular and all-cause mortality
when compared with patients with higher blood pressure,
raising the possibility that strict blood pressure control
could have adverse health consequences [16]. However,
these studies had not considered physical performance and
had not controlled for use of antihypertensive medication.Although lower postdialysis blood pressure has also been
associated with higher mortality [20], we limited our ana-
lysis to predialysis blood pressure because physical function
testing was performed prior to hemodialysis. Fluid overload
could have caused an increase in predialysis blood pressure
and worse physical function scores, but these associations
would bias the results to the null.
End-stage kidney disease may be a model of accelerated
aging, with cardiovascular and muscle mass changes typic-
ally observed in the elderly occurring even among younger
patients [21]. Recent studies, focusing on the concept of
physiologic age, have stratified outcomes in elderly based
on physical performance tests [4]. The physiologic similar-
ities between elderly and hemodialysis patients and the
need for higher blood pressures to maintain adequate sys-
temic perfusion could explain the association between
higher systolic blood pressure and better physical function
that we observed. We determined that patients with blood
pressure <110 mmHg did not have significantly worse
physical function than the 110-129 mmHg reference
group which suggests that both traditional targets and
Figure 2 Odds ratio of lower performance category for each test based on predialysis systolic blood pressure category.
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physical performance than higher blood pressure levels in
this patient population.
Neither history of heart failure nor lower hemoglobin
was significantly associated with a higher odds of being
in the lowest SPPB in multivariable analysis. The lack of
association with heart failure could be because the SPPB
is a brief test that emphasizes mobility and strength and
is not a test of endurance. Alternatively, the lack of asso-
ciation could reflect the common tendency for dialysis
patients with fluid overload to be given a diagnosis of
heart failure even in the absence of a structural cardiac
abnormality. The association between albumin and phys-
ical performance was expected as higher albumin is re-
flective of better nutritional status or less inflammation.
The association between physical performance and dia-
betes mellitus has also been described previously [19].
When we examined the individual components of the
SPPB, we found that gait speed and sit to stand were
better among patients with higher blood pressure, but
we did not find an association between the balance com-
ponent of the SPPB and blood pressure. These findings
are compatible with the hypothesis that dynamic balance
and function may be more susceptible to the effects of
blood pressure than static balance.
To put the SPPB scores in context, the SPPB score has
been predictive of mortality and nursing home admis-
sions in elderly populations. ACTIVE/ADIPOSE partici-
pants had a lower percentage of participants scoring in
the highest category (10-12) and a higher percentage
scoring in the lowest category when compared with the
70-year old Established Populations for Epidemiologic
Studies of the Elderly (EPESE) cohort. [13] SPPB scores
in our participants can be compared to those of partici-
pants in the Frequent Hemodialysis Network (FHN)
trial. The mean SPPB score in our cohort (7.8, SD 3.9)
was lower than among FHN participants (8.5) who mayhave been a healthier, more selected population. Indeed,
participants in our study were older (57.3 vs. 50.7 years).
Older age, African-American race, diabetes mellitus, and
peripheral arterial disease were all associated with lower
SPPB scores among FHN participants, similar to our
findings [19]. However, the association between systolic
predialysis blood pressure and physical function was not
addressed in the FHN.
Strengths of our study include careful direct measure-
ment of physical performance and use of the SPPB, which
allows comparison with other dialysis and non-dialysis
populations. Information about prescription medication
was carefully collected and available for analysis. Never-
theless, several limitations of our study should be ad-
dressed. First, we relied on blood pressure data that were
obtained in clinical practice rather than under carefully
controlled conditions. Although this could introduce some
additional variation, such variation would tend to bias our
results to the null. In addition, our data mirror the infor-
mation that physicians have available for clinical decision-
making. Second, the cross-sectional analyses precluded us
from determining whether low blood pressure itself led to
poor physical performance as we hypothesized or if
patients with poor physical performance had low blood
pressures due to unmeasured comorbidities. Third, we did
not have information on whether patients were taking
antihypertensive medications as prescribed or the indica-
tion for the prescribed medication. Fourth, we relied on
diagnostic codes for heart failure, without capturing
detailed echocardiographic data on cardiac function, so we
could not determine whether differences in cardiac func-
tion might have contributed to the observed results.
Conclusion
Our findings demonstrate an association between lower
blood pressure and poorer physical performance among a
cohort of patients on hemodialysis. The association was
Abreo et al. BMC Nephrology 2014, 15:177 Page 7 of 8
http://www.biomedcentral.com/1471-2369/15/177present regardless of age or antihypertensive therapy. Al-
though management decisions cannot be based upon these
data alone, these findings raise the possibility that aggres-
sive blood pressure control in patients on hemodialysis
could lead to adverse consequences, and the risk-benefit
tradeoff of aggressive blood pressure control, particularly
in low-functioning hemodialysis patients, should be reexa-
mined. In addition, future randomized trials of blood pres-
sure control among hemodialysis patients should include
physical performance measures.Abbreviations
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